# Molbio Diagnostics shares list at 21% premium at ₹980 2026-08-17T06:46:57+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 3 independent outlets Molbio Diagnostics debuted on the stock market on Monday with shares listing at ₹980 on both the BSE and NSE, a premium of 21.4 per cent over the issue price of ₹807. The company raised approximately Rs 940 crore through its IPO, which was subscribed 70.26 times. The stock touched a high of ₹1,002.05 intraday before profit-booking pulled it to around ₹926. The IPO comprised a fresh issue of Rs 200 crore and an offer-for-sale of up to 91.66 lakh shares by existing shareholders. Proceeds from the fresh issue will fund a new R&D facility, Centre of Excellence, and machinery for manufacturing units in Goa and Visakhapatnam. The Goa-based firm is known for its Truenat platform, a battery-operated point-of-care PCR device used to diagnose 30 diseases including TB, Covid, and HIV. Analysts noted the listing defied weak broader market sentiment. The grey market premium on Monday morning was Rs 120, indicating expectations of a 15 per cent gain. Shares were credited to successful bidders on 14 August. ## Indian Opinion Analysis All three sources report the same central fact: Molbio Diagnostics listed at a 21% premium on its IPO day. The Hindu Business Line and Business Today lead with the strong debut and the company's growth narrative, emphasising the subscription level, use of funds, and global expansion plans. Livemint provides a more market-oriented report, highlighting that the listing defied weak market sentiment and that profit-booking pulled the stock down soon after. Livemint also includes grey market data to contextualise the listing performance. There is no disagreement between sources, but Livemint's framing is cautious, adding detail about post-listing volatility that the others omit. The measured takeaway is that while the listing was strong, early trading suggests some profit-taking. Watch for the stock's performance in the coming sessions to gauge sustained investor appetite. ## Coverage Coverage: 3 sources, 3 neutral - thehindubusinessline.com (neutral report) Leads with strong listing and subscription data, frames IPO as successful, focusing on company growth plans - livemint.com (neutral report) Leads with listing performance but also reports immediate profit-booking, adds market context and grey market premium - businesstoday.in (neutral report) Leads with listing premium and CEO interview, frames IPO capital as fuelling R&D and global expansion This story was synthesised by AI from the 3 sources linked above. Updated: this story now draws on 3 sources. Last updated 2026-08-18T11:11:45+00:00. Tags: BSE, Molbio Diagnostics, NSE, Truenat Canonical: https://indianopinion.org/molbio-diagnostics-shares-debut-at-21-premium-on-bse-nse/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/molbio-diagnostics-shares-debut-at-21-premium-on-bse-nse/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/